MedTrace Logo

Evaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine

NCT07263295 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-12-04

No results posted yet for this study

Summary

The study aims to evaluation the effects of Liposomal Bupivacaine on diaphragmatic function in patients undergoing upper limb surgery who receive Interscalene Brachial Plexus Block. A total of 120 eligible patients will be enrolled and divided into two groups: Group A will receive 20ml of 0.5% Hydrochloride Bupivacaine , while Group B will receive 10ml of 0.5% Hydrochloride Bupivacaine plus 10ml of Liposomal Bupivacaine. Assessments of diaphragmatic function, pulmonary function, and pain intensity will be performed before the block and at different time points after the block, with follow-up for adverse events. The study is scheduled to run from September 2025 to September 2026, with strict adherence to privacy protection and ethical guidelines.

Conditions

  • Diaphragmatic Function
  • Metacarpal Fracture
  • Radius Fracture
  • Peripheral Nerve Neurolysis
  • Chronic Ulcer
  • Upper Extremity Ligament Injury

Interventions

DRUG

0.5% Hydrochloride Bupivacaine 20ml

0.5% Hydrochloride Bupivacaine 20ml for ISBPB

DRUG

0.5% Hydrochloride Bupivacaine 10ml

0.5% Hydrochloride Bupivacaine 10ml for ISBPB

DRUG

Liposomal Bupivacaine 10mL

Liposomal Bupivacaine 10mL for ISBPB

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-05
Primary Completion
2026-09-20
Completion
2026-12-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07263295 on ClinicalTrials.gov